Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety
Speaker: W. Frank An, PhD.
Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals
Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. Dr. W. Frank An outlined the current progress in the BsADC field and highlight Biocytogen’s ongoing BsADC programs.